DeepMed Research

JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

The CANTATA-M (CANagliflozin Treatment and Trial Analysis - Monotherapy) Trial

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: Canagliflozin
Drug: Sitagliptin

First Posted Date: 2010-03-05

Last Posted Date: 2017-02-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 678

Registration Number: NCT01081834

A Study of the Safety and Efficacy of Ustekinumab in Patients With Psoriatic Arthritis With and Without Prior Exposure to Anti-TNF Agents

Phase 3

Completed

Conditions: Arthritis, Psoriatic

Interventions: Drug: placebo
Drug: ustekinumab 90 mg
Drug: ustekinumab 45 mg

First Posted Date: 2010-03-01

Last Posted Date: 2014-02-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 312

Registration Number: NCT01077362

An Efficacy, Safety, and Tolerability Study of Canagliflozin in Patients With Type 2 Diabetes Mellitus Who Have Moderate Renal Impairment

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Renal Insufficiency

Interventions: Drug: Placebo
Drug: Canagliflozin

First Posted Date: 2010-02-08

Last Posted Date: 2013-08-14

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 272

Registration Number: NCT01064414

The Asia-Pacific Flexible Dose Study of Dapoxetine and Patient Satisfaction in Premature Ejaculation Therapy

Phase 3

Completed

Conditions: Sexual Dysfunction, Physiological

Interventions: Drug: Dapoxetine

First Posted Date: 2010-02-05

Last Posted Date: 2024-11-19

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 285

Registration Number: NCT01063881

A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia

Phase 3

Completed

Conditions: Schizophrenia

Interventions: Drug: Paliperidone palmitate

First Posted Date: 2010-01-18

Last Posted Date: 2024-10-28

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 546

Registration Number: NCT01051531

CANVAS - CANagliflozin cardioVascular Assessment Study

Phase 3

Completed

Conditions: Diabetes Mellitus, Type 2
Cardiovascular Diseases
Risk Factors

Interventions: Drug: Placebo
Drug: Canagliflozin (JNJ-28431754) 100 mg
Drug: Canagliflozin (JNJ-28431754) 300 mg

First Posted Date: 2009-12-15

Last Posted Date: 2018-12-07

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 4330

Registration Number: NCT01032629

A Study to Evaluate the Efficacy and Safety of CNTO328 Plus Best Supportive Care in Multicentric Castleman's Disease

Phase 2

Completed

Conditions: Multicentric Castleman's Disease

Interventions: Drug: Placebo
Drug: Siltuximab
Drug: Best Supportive Care (BSC)

First Posted Date: 2009-12-02

Last Posted Date: 2018-03-21

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 79

Registration Number: NCT01024036

An Observational Study of Men With Premature Ejaculation Who Are Treated With Dapoxetine Hydrochloride or Alternate Care Defined as Any Treatment Other Than Dapoxetine Hydrochloride

Completed

Conditions: Ejaculation
Sexual Dysfunction, Physiological

Interventions: Other: Alternate care/non-dapoxetine hydrochloride treatment(s)
Drug: Dapoxetine hydrochloride

First Posted Date: 2009-11-30

Last Posted Date: 2013-11-26

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 10027

Registration Number: NCT01021670

A First in Man Study of MABp1 in Patients With Advanced Cancers

Phase 1

Completed

Conditions: Advanced Cancers

Interventions: Drug: MABp1

First Posted Date: 2009-11-26

Last Posted Date: 2021-02-16

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 52

Registration Number: NCT01021072

Locations: 🇺🇸
M.D. Anderson Cancer Institute, Houston, Texas, United States
🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States

A Drug-Drug Interaction Study of Abiraterone Acetate Plus Prednisone With Dextromethorphan and Theophylline in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 1

Completed

Conditions: Prostate Neoplasms

Interventions: Drug: Abiraterone acetate
Drug: Prednisone
Drug: Theophylline
Drug: Dextromethorphan hydrobromide

First Posted Date: 2009-11-23

Last Posted Date: 2013-04-12

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 34

Registration Number: NCT01017939

Locations: 🇺🇸
START - South Texas Accelerated Research Therapeutics, LLC, San Antonio, Texas, United States
🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇨🇦
BC Cancer Agency, Vancouver, British Columbia, Canada

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy